Clinical Trials Browser

Phase 1/2 × INDUSTRY × TAK-659 × Clear all

NCT02323113 2023-02-08

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Phase 1/2 Terminated

43 enrolled 27 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute